AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...
Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...
Elizabeth Yeu, MD, provides a comprehensive overview of Demodex blepharitis stemming from infestations of eyelash follicle mites. In this video segment featuring Dr. Elizabeth Yeu, an expert in ...
The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex mites, ...
Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...
Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...
IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results